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Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. Fourteen sarcomeric and sarcomere-related genes
have been implicated in HCM etiology, those encoding b-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3)
reported as the most frequently mutated: in fact, these account for around 50% of all cases related to sarcomeric gene mutations, which
arecollectively responsible forapproximately 70%ofallHCMcases.Here,we useddenaturing high-performanceliquid chromatography
followedbybidirectionalsequencingtoscreenthecodingregionsofMYH7andMYBPC3inacohort(n¼125)ofItalianpatientspresenting
with HCM. We found 6 MHY7 mutations in 9/125 patients and 18 MYBPC3 mutations in 19/125 patients. Of the three novel MYH7
mutations found, two were missense, and one was a silent mutation; of the eight novel MYBPC3 mutations, one was a substitution, three
were stop codons, and four were missense mutations. Thus, our cohort of Italian HCM patients did not harbor the high frequency of
mutations usually found in MYH7 and MYBPC3. This ﬁnding, coupled to the clinical diversity of our cohort, emphasizes the complexity of
HCM and the need for more inclusive investigative approaches in order to fully understand the pathogenesis of this disease.
J. Cell. Physiol. 226: 2894–2900, 2011.  2011 Wiley-Liss, Inc.
Hypertrophic cardiomyopathy (HCM) is the most common
genetic disease of the myocardium, occurring in about 1:500
individuals in the general population (Maron et al., 1995;
Bos et al., 2009). It is characterized by usually asymmetric left
ventricular (LV) hypertrophy in the absence any obvious cause,
suchashypertension(Chungetal.,2003).Theclinicalcourseof
HCMisextremelydiverse:manypatientsremainasymptomatic
throughout life, others develop symptoms of atrial ﬁbrillation
and/orheartfailure,andsomediesuddenly,oftenatayoungage
and without previous symptoms—indeed, HCM is the most
commoncauseofsuddencardiacdeathinathletes(Maronetal.,
1980; Alcalai et al., 2008).
HCM is an autosomal dominant disorder and, to date, >500
distinct mutations in 14 genes encoding sarcomeric or
sarcomere-relatedproteinshavebeenimplicatedinitsetiology
(Marian and Roberts, 2001; Seidman and Seidman, 2001).
However, these account for only 70% of genetically tested
HCMpatients(Marian,2001).Recently,twoormoresequence
alterationspresenteitherinthesameorindifferentsarcomeric
genes (compound or double heterozygosity) were
Additional Supporting Information may be found in the online
version of this article.
Contract grant sponsor: Telethon;
Contract grant number: TIGEM-TNP42TELC.
Contract grant sponsor: Ministero della Salute;
Contract grant numbers: RF-MUL-2007-666195, RFPS-2006-2-
335458.
Contract grant sponsor: Ministero della Ricerca Scientiﬁca.
Roberta Roncarati’s present address is Istituto di Neurobiologia e
Medicina Molecolare (INMM), CNR, Rome, Italy.
*Correspondence to: Gianluigi Condorelli, Via Fantoli 16/15,
Milano 20138, Italy. E-mail: gcondorelli@ucsd.edu
Received 29 October 2010; Accepted 3 January 2011
Published online in Wiley Online Library
(wileyonlinelibrary.com), 1 February 2011.
DOI: 10.1002/jcp.22636
ORIGINAL RESEARCH ARTICLE 2894
Journal of Journal of
Cellular
Physiology
Cellular
Physiology
 2011 WILEY-LISS, INC.demonstrated to occur in 3–5% of HCM patients (Ingles et al.,
2005; Keren et al., 2008). The presence of multiple gene
mutations is often associated with a greater clinical severity of
the disease (Felker et al., 2000; Chien, 2003; Ingles et al., 2005).
Unfortunately, the relationship between genotype and
phenotype is complex for HCM and is still challenging.
The goal of the present study was to identify the genetic
variations (mutations and single nucleotide polymorphisms—
SNPs) present in the two sarcomeric protein genes that have
been reported to account for about 50% of genotyped cases of
HCM(VanDriestetal.,2005;Kerenetal.,2008),thatis,MHY7,
which encodes b-myosin heavy chain (Geisterfer-Lowrance
et al., 1990), and MYBPC3, encoding cardiac myosin binding
protein(Watkinsetal.,1995),andﬁndanycorrelationbetween
thevariationdetectedandtheclinicalphenotypepresented.To
this end, we used denaturing high-performance liquid
chromatography (DHPLC) followed by direct sequencing
(Sanger) to screen a cohort of Italian patients with HCM.
Unexpectedly,weidentiﬁedonly6and18distinctmutations,
respectively, in MYH7 and MYBPC3—of which, respectively, 3
and 8 were novel—in a total of only 22.4% of our unrelated
patients.Moreover,apaucityofsigniﬁcantgenotype/phenotype
correlations indicated the impossibility of clinically
differentiating HCM on the basis of only these two selected
sarcomeric genes.
Materials and Methods
Clinical evaluation of patients
One hundred thirty-six Italian patients (n¼125 unrelated)
diagnosed with HCM between 2005 and 2007 by cardiologists at
the dedicated cardiomyopathy outpatient clinic of Azienda
Ospedaliera Sant’Andrea, Sapienza University of Rome, were
enrolledforthestudy.ThestudywasapprovedbytheInternalEthic
Committee of Azienda Ospedaliera Sant’Andrea, and all
participants gave written informed consent to be included in the
study. Patients with any relative diagnosed with HCM were
considered familial cases, and patients without a family history of
HCMandaffectedrelativeswereconsideredsporadiccases.When
carriers were found, screening was suggested for ﬁrst-degree
family members.
All probands and relatives underwent physical examination,
12-lead electrocardiogram, two-dimensional echocardiography,
Doppler studies, and 24-h Holter monitoring. The diagnosis
of HCM was based on echocardiographic demonstration of a
hypertrophied and non-dilated left ventricle (wall thickness
 15mminadults,ortheequivalentrelativetobodysurfaceareain
children) in the absence of other cardiac or systemic diseases that
couldproduceacomparablemagnitudeofLVhypertrophy(Spirito
et al., 2000). The greatest thickness measured at any site in the LV
wall was considered to represent the maximal wall thickness
(Spirito et al., 2000). End-diastolic LV cavity and left atrial
dimensions were assessed from the derived M-mode
echocardiogram. LV outﬂow tract obstruction was considered
present when the peak instantaneous outﬂow gradient estimated
by continuous wave Doppler was  30mm Hg under basal
conditions (Maron et al., 2003; Autore et al., 2005).
Genetic analysis
Sample preparation. Aliquots of 5ml of peripheral blood were
collected in tubes containing EDTA. Genomic DNA was extracted
using DNA Qiamp Midi kit (QIAGEN, Crawley, UK) according to the
manufacturer’s instructions. The suitability for sequencing of genomic
DNA was veriﬁed spectrophotometrically (Thermo Fisher Scientiﬁc,
Barrington, IL).
PCR primers and exon ampliﬁcation for DHPLC. Muta-
tional analysis of the exons and exon/intron boundaries (at least 35
intron nucleotides from the junctions) of MYH7 and MYBPC3 was
carried out with DHPLC. For all samples with an abnormal DHPLC
elution proﬁle, the putative sequence anomaly was investigated by
automated dye terminator cycle (bidirectional) sequencing. Primer
pairs were designed to amplify MYH7 and MYBPC3 exon-containing
fragments. Primers were compared by the web-based Primer3
program (PRIMER3; primer3_www.cgi, v 0.2; http://frodo.wi.mit.edu).
Each oligonucleotide was also checked by Blast against the NCBI data
bank genome for speciﬁcity (BLAST, www.ncbi.nlm.nih.gov/BLAST;
NCBI, www.ncbi.nlm.nih.gov). Primer sequences are given in
Supplementary Tables S1 (MYH7) and S2 (MYBPC3). PCR reactions
were set up in 25ml containing the following: 15pmol of each primer,
1  PCR buffer with 1.5mM magnesium chloride, 200mM of each
deoxynucleotide triphosphate (Amersham, Little Chalfont, UK),
1.25U of Ampli-Taq Gold DNA polymerase (Applied Biosystems,
Foster City, CA), and 60ng of DNA. The conditions used were as
follows: a denaturation step at 958C for 7min; 34 cycles at 958C for
30sec., annealing at 608C for 90sec, and extension at 688C for 60sec,
adding3secforeachcycle;aﬁnalextensionat688Cfor10min.AllPCR
reactions were carried out in a PCR Express Thermalcycler (Celbio,
Milan, Italy). The same annealing temperature for all the exons was
used, allowing different exons to be ampliﬁed in the same 96/384-well
plate. The PCR products were stored at 48C before DHPLC analysis.
Experimental conditions for DHPLC. DHPLC analysis was
carried out with the WAVE DNA fragment analysis system, using
models 3500A and 3500HT (Transgenomic, Omaha, NE). A PCR size
range of 150–450bp was used in order to reach >95% sensitivity. The
PCR mixture (5–8ml) was injected into a preheated C18 reversed-
phase column with non-porous (polystyrene/divinylbenzene) particles
(DNASepTM column; Transgenomic). The injected sample was then
eluted by a linear acetonitrile gradient consisting of buffer A and buffer
B. DNA was detected at 260nm. Melting curves were predicted using
Wavemaker software (Transgenomic), and a comparison of the
retention times at different temperatures was performed withcontrol
fragments bearing known variations. Each variation was usually
detectable in a range of  1.58C. The typical analytical gradient time
was3.5minwiththe3500Amodeland2.5minwiththe3500HTmodel.
Buffer B concentration was increased at 2% per min.
DNA sequencing. The PCR amplicons were puriﬁed with Exo-
Sap enzymes (Applied Biosystems) and then sequenced. Direct
sequencing was performed by automated cycle sequencing with a
3130XL Genetic Analyzer (Applied Biosystems). The sequencing
reaction was performed with the following protocol: 2.5pM/ml for
each primer (forward or reverse), 2ml of Big Dye Terminator mix
(Perkin Elmer, Boston, MA) containing dideoxyribonucleotides,
deoxyribonucleotides, a Taq polymerase, 5  TACS buffer (400mM
Tris–HCl, pH 8, 10mM MgCl2, and 100mM SO4(NH4)2, pH 9), 5mlo f
DNA (100ng), and H2O to a ﬁnal volume of 10ml. At the end of the
sequencing reaction the samples were puriﬁed on a Sephadex G50
membranebycentrifugationat1,700rpmfor2min;5mlofthepuriﬁed
sample thus obtained was added to 10ml of deionized formamide and
denaturedfor3minat958Cbeforebeingsubjectedtoelectrophoresis.
TheelectrophoresisapparatususedwasanABIPRISM3100automatic
sequencer (Applied Biosystems).
Statistical analysis
All continuous data are given as mean SD. Baseline
characteristics between two groups were analyzed by Student’s
t-test for continuous variables and by the Fisher exact test for
categorical data.
Results
Patients
The clinical characteristics, including electrocardiographic and
echocardiographicdata,ofthepatientsaregiveninTable1(see
also Supplementary Table S3). Most of the patients (87.2%)
were born in Rome or in other parts of the Lazio region; 16
were from other regions of Italy. Fifty-one had a family history
of HCM. The majority of patients (92%) were asymptomatic or
mildly symptomatic; 10 had moderate or severe symptoms of
heart failure (NYHA class III–IV) and 6 had progressed to the
‘‘end-stage phase’’ of the disease, with impaired LV systolic
function (ejection fraction <50%). At echocardiography, 40
patients presented with an LV outﬂow tract obstruction. In
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septum, whereas it was apical in only 12. Interventions and
events are also given in Table 1. In 19 patients judged to be at
highriskofsuddendeath,acardioverter-deﬁbrillator(ICD)had
been implanted as a primary prevention; 4 of them had already
experienced one appropriate intervention (ICD intervention).
Two patients experienced non-fatal stroke and another
underwent myotomy/myectomy.
Genetic analysis
Thirty-two individuals in our cohort of 136 HCM patients
(23.5%) were found carrying mutations: of these, 28 were
unrelated, accounting for 22.4% of the 125 unrelated patients.
Speciﬁcally, 6 distinct mutations were found in MHY7 in 9/125
(7.2%)patientsand18distinctmutationswerefoundinMYBPC3
in 19/125 (15.2%) patients (Tables 2 and 3, respectively). All
mutations were in heterozygosis. Multiple mutations, present
either within the same gene or in both genes
contemporaneously, were not encountered. A total of 384
chromosomes from healthy, unrelated Italian subjects were
used as controls.
Mutations in MYH7
Six variations present in MYH7 (4.8%) were distinct mutations
that were not found in the control group (Table 2a). Three
were novel and carried by 4/125 (3.2%) patients, whereas the
other 3/6 were known mutations harbored by 5/125 (4%)
patients.
Novel mutations. Two of the mutations found (N444S and
D1652Y) were novel missense mutations. A third (A1051A)
was a silent mutation harbored by two unrelated patients.
Figure 1 gives the location of these novel mutations in a
schematic representation of the MYH7 protein.
Electropherograms and chromatograms for the novel
mutations found in MYH7 are given in Supplementary Figure 1.
Knownmutations. Threeofthemutationsencounteredare
alreadylistedinpublicdatabases:L517Misamissensemutation
that has a pathogenic effect and has been linked to HCM with
progression to dilated cardiomyopathy (Nanni et al., 2003);
M932K is another missense mutation (Iascone et al., 2007);
S1491C (Hougs et al., 2005) was found in four of our subjects
(two unrelated patients and a mother/daughter pair).
Mutations in MYBPC3
Eighteen distinct mutations were found in MYBPC3 (14.4%):
ﬁve were potential alternative splicing sites (all generated by
nucleotidesubstitutions),sevenwerestopcodons(fourcaused
TABLE 1. ClinicalFeaturesofUnrelatedHCMPatientsatTimeofGenetic
Testing
Clinical features Patients (nU125)
Men (%) 79 (63.2)
Age at study (yrs) 54.2 16
b
Age at diagnosis (yrs) 40.7 18
b
Family history of HCM (%) 51 (40.8)
Family history of SCD (%) 38 (30.4)
NYHA III–IV functional class (%) 10 (8.0)
Chest pain (%) 55 (44.0)
Syncope (%) 19 (15.2)
NSVT (%) 14 (10.9)
Atrial ﬁbrillation
a (%) 16 (12.8)
Electrocardiographic analysis
LVH (%) 79 (63.2)
Q wave (%) 39 (31.2)
T wave inversion (%) 82 (65.6)
Echocardiographic features
LVOT obstruction (%) 40 (32.0)
Left atrium (mm) 45.5 7
b
Maximum LVWT (mm) 19.9 5
b
LVEF (%) 65.1 7
b
Localization of hypertrophy
Anterior septum (%) 97 (77.6)
Posterior septum (%) 6 (4.8)
Lateral wall (%) 10 (8.0)
Apical wall (%) 12 (9.6)
Interventions and events
ICD (%) 19 (15.2)
Myotomy/myectomy (%) 1 (0.8)
Alcohol septal ablation (%) 0 (0)
End stage evolution (%) 6 (4.8)
Stroke (%) 2 (1.6)
ICD intervention (%) 4 (3.2)
Yrs,years;SCD,suddencardiacdeath;NYHAIII–IV,NewYorkHeartAssociationclassIII–IV
(classiﬁcation of heart failure); NSVT, non-sustained ventricular tachycardia; ECG, electro-
cardiogram; LVH, left ventricular hypertrophy; LVOT, left ventricular outﬂow tract; LVWT,
left ventricular wall thickness; LVEF, left ventricular ejection fraction; ICD, implantable
cardioverter deﬁbrillator.
aEither paroxymal or permanent.
bMean SD.
TABLE 2. Variations Detected on MYH7
M by DHPLC Followed by Direct Sequencing
MM
DNA variation Exon Type of mutation Protein mutation Novel Patient ID
Panel (a) mutations
a
c.1331 A>G 12 Missense N444S Yes 154
c.2795 T>A 21 Missense M932K No 201
c.4954 G>T 33 Missense D1652Y Yes 183
c.4472 C>G 30 Missense S1491C No 190
c,1 9 9
,c, 206, 293
c.1549 C>A 13 Missense L517M No 248
c.3153 G>A 23 Silent A1051A Yes 273, 227
DNA variation Exon/intron Type of SNP Protein variation Novel
d Patient ID
Panel (b) SNPs
c.732 C>T Exon 6 Synonymous
b F244F rs2069542 219, 299, 93, 230, 273, 255
c.597 A>G Exon 5 Synonymous A199A rs2069541 291, 260, 288, 289, 189
c.2967 T>C Exon 22 Synonymous I989I Yes 167, 217
c.4566 T>C Exon 31 Synonymous
b T1522T Yes 172
c.4193A>T Exon 29 Non-synonymous Q1398L Yes 182
 110 t>c  110 t>c 5’ UTR — Yes 162, 95, 165, 242
c3855þ27 t>a Intron 26 — c.3855þ27t>a Yes 173, 203, 229, 255, 261, 280, 299
c.5655þ32 g>a Intron 36 — c.5655þ32g>a Yes 173, 203, 280, 284, 290
 Protein: GenBank NP_000248; cDNA: GeneBank NM_000257 Reverse strand.
  Carried out on exons and intron/exon boundaries (from a minimum of 35 up to 50 bases) in 136 subjects.
aAll variations were in heterozygosis.
bPotential splicing alteration.
cDaughter and mother.
dSNPIDisgivenforknownSNPs.Novelmutationswereabsentinthehealthycontrols(n¼192).TheCardiogenomicsandHumanGenomeMutationdatabaseswereusedtoassignthestatusof
novel mutation—known mutations were not tested in controls.
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generating frameshifts), and six were missense mutations
(Table 3a). Nine (7.2%) unrelated patients harbored novel
mutations, whereas 10/125 (8%) carried known mutations.
Three ofthemutations werepresentinmore than one patient.
Novel mutations. Eight out of the 18 mutations detected
(6.4%) were novel: c.2905þ1 was a substitution potentially
causingtheexcisionofexon25throughalteredsplicing;3were
mutations that produced premature stop codons, 1 of which
(R493X) was caused by a nonsense nucleotide substitution and
2 of which were caused by nucleotide insertions (M949IfsX100
and K754EfsX78); the remaining 4 (T885M, R668C, L1084P,
and R810Q) were missense mutations with a probable
pathogenic effect caused by the substitution of an amino acid.
L1084P was detected in a father/son pair, and the novel
insertion K754EfsX782 was carried by two unrelated patients,
one of which (patient ID 195) presented also with a delC in
intron 4, only 12bp upstream of exon 5. Figure 2 is a schematic
summary of the novel variations recorded. Electropherograms
and chromatograms for novel mutations detected in MYBPC3
are given in Supplementary Figure 2.
Known mutations. Ten out of the 18 mutations detected
(8%)arealreadydescribedinpublicmutationdatabases:A364T
(Smaniotto et al., 2009), D605H (Alders et al., 2003), E542Q
(Carrier et al., 1997), and c.2309-2A>G (Niimura et al., 2002)
are substitutions potentially generating splicing alterations, the
last one found in the intronic side of the junction and D605H
harbored by three related patients (father, son, and nephew);
three(Q969X,Q1012X,andQ1233X)arenonsensemutations
creating stop codons in exons 25, 27, and 31, respectively
TABLE 3. Variations Detected on MYBPC3
M With DHPLC Followed by Direct Sequencing
MM
DNA variation Exon Type of mutation Protein mutation Novel Patient ID
Panel (a) mutations
a
c.1090G>A 11 Potential splicing alteration A364T No 233
c.1813G>C 17 Potential splicing alteration D605H No 180
c,1 8 6
,c, 208
,c
c.1624G>C 15 Potential splicing alteration E542Q No 244
c.2309-2A>G 22 Potential splicing alteration 2309 2N o 2 3 4
c.2905þ1G>A 25 Potential splicing alteration
b 2905þ1 Yes 157
c.2905C>T 25 Nonsense: STOP codon Q969X No 188
c.2827C>T 25 Nonsense: STOP codon R493X Yes 220
c.3034C>T 27 Nonsense: STOP codon Q1012X No 181
c.3697C>T 31 Nonsense: STOP codon Q1233X No 251
c.2846–2847InsT 25 Frameshift: STOP codon M949IfsX100 Yes 278
c.2258–2259InsT 21 Frameshift: STOP codon K754EfsX78 Yes 195, 228
c.3192–3193InsC 28 Frameshift: STOP codon K1065QfsX11 No 194
c.2654C>T 24 Missense T885M Yes 265
c.2002C>T 19 Missense R668C Yes 214
c.3251T>C 28 Missense L1084P Yes 177
d,1 8 5
,d
c. 2311G>A 22 Missense V771M No 221
c.2429 G>A 25 Missense Arg810His Yes 270
c.1373G>A 14 Missense R458H No 268
DNA variation Exon/intron SNP Novel
e Protein variation Patient ID
Panel (b) SNPs
c.472G>A Exon 4 Non-synonymous rs3729986 V158M 270
c.977G>A Exon 11 Non-synonymous rs34580776 R326Q 251
c.1564 G>A Exon 15 Non-synonymous rs11570082 A522T 221
c.492 C>T Exon 4 Synonymous rs3218719 G164G 214
c.2550 C>T Exon 23 Synonymous rs3729953 V849V 278, 251, 268
c.3288 G>A Exon 28 Synonymous rs1052373 E1096E 234
c.506–12 Intron 4 — Yes delC 195, 251, 270
c.1223þ29 G>A Intron 12 Synonymous rs11570078 — 181, 221, 194
c.2340þ18 C>G Intron 21 Synonymous rs3729948 — 278, 251 268, 194
c.2737þ12 C>T Intron 24 Synonymous rs3729936 — 251, 268, 194
 Protein: GenBank NP_000247.2; cDNA: GenBank NM_000256.3 reverse strand.
  Carried out on exons and intron/exon boundaries (from a minimum of 35 up to 50 bases) in 136 subjects.
aAll variations were in heterozygosis.
bPossible exclusion of exon 25.
cRelated (father, son, and nephew).
dRelated (father and son).
eSNPIDisgivenforknownSNPs.Novelmutationswereabsentinthehealthycontrols(n¼192).TheCardiogenomicsandHumanGenomeMutationdatabaseswereusedtoassignthestatusof
novel mutation—known mutations were not tested in controls.
Fig. 1. Schematic representation of homosapiens b-myosin heavy
chainprotein andthelocationofthenovel mutations(nU3)andnon-
synonymous SNP found in the 136 HCM patients analyzed. Red,
missense mutations; black, silent mutation; blue, non-synonymous
SNP.
Fig. 2. Schematic representation of the location of the novel
mutations (nU8) and the non-synonymous SNPs (nU3) detected
within cardiac myosin binding protein in the 136 HCM patients
analyzed. Novel mutation 2905R1 (exon 25) is not shown. Red,
missense mutations; purple, nonsense mutations producing stop
codons; blue, non-synonymous SNPs.
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GENETIC VARIATIONS IN MYH AND MYBPC3 IN HCM 2897(Yu et al., 1998; Erdmann et al., 2001; Nanni et al., 2003);
K1065QfsX11 (Girolami et al., 2006) is a nucleotide insertion
generating, through a frameshift, a premature stop codon in
exon 28; V771M (Garcia-Castro et al., 2005); and R458H (Van
Driestetal.,2004)aremissensemutationscausedbyaminoacid
substitutions in exon 22 and 14, respectively (Cardiogenomics
Mutation Database, 2005; HGMD, http://www.hgmd.cf.ac.uk/
ac/all.php).
Polymorphisms
In addition to the above mutations, we found several SNPs.
MYH7. We found 6 distinct novel SNPs in MYH7 in 31
patients.AllbuttwooftheseSNPsweredetectedinmorethan
one patient (Table 2b): three (I989I, T1522T, and Q1398L)
resided in the coding region—except for Q1398L these were
synonymous variations; three were nucleotide substitutions
present either in the 5’UTR ( 110t>c), in intron 26
(c.3855þ27t>a), or in intron 36 (c.5655þ32g>a). F244F and
T1522Tweresubstitutionsofthelastnucleotideofexons6and
31, respectively, causing possible splicing alterations. Only two
distinct synonymous SNPs (F244F and A199A) have already
been described (http://cardiogenomics.med.harvard.edu/
home). At the moment, we can only indicate these genetic
alterations as polymorphisms of doubtful etiologic role in that
they were not found in 384 chromosomes from control
subjects.
MYBPC3. Ten different SNPs where found in MYBPC3 in 21
patients;5oftheseSNPswerefoundtobepresentinmorethan
1 patient (Table 3b). Three were non-synonymous changes
(rs3729986—V158M—carried by R810Q, rs34580776—
R326Q—carried by Q1233X, and rs11570082—A522T—
carried by V771M) with a potential functional effect on the
protein.SixwereknownsynonymousSNPs.Onlyone,adelCin
intron 4, was a novel SNP found in multiple patients (Table 3b).
Prediction of the missense mutations’ effect on the
protein, and genotype/phenotype correlation
To obtain more functional information on those mutations
and polymorphisms that caused an amino acid change, we used
the in silico bioinformatic tool PolyPhen (http://genetics.bwh.
harvard.edu/pph/) to functionally classify the novel variations
detected. PolyPhen categorizes variations to indicate the
predicted effect on the protein as benign, possibly damaging,
or probably damaging.
MYH7. N444S, D1652Y, and L517M were predicted to
be damaging for the function of the protein, whereas M932K
and S1491C were deﬁned as benign (Table 4a). The novel
non-synonymous SNP Q1398L was also predicted as being
damaging.
MYBPC3. According to PolyPhen software, R668C,
L1084P, A364T, T885M, and R810Q have a deleterious
effect on the protein, whereas V771M, E542Q, D605H, and
R458Hseemtobetolerated.Inaddition,thepredictedeffectof
the two known non-synonymous SNPs rs3729986 and
rs11570082, which generatedV158M andA522T, respectively,
were classiﬁed as benign (Table 4b).
Genotype/phenotype correlation. Even though our clinical
database is detailed, establishing signiﬁcant correlations
between genotype and phenotype was limited by the small
sample size. We found only poor correlations between the
predicted effect of each novel mutation on the protein, as
established by PolyPhen software, and the clinical proﬁle of
patients carrying those mutations (Supplementary Tables S4
andS5). However,wefoundthatamongthe novelmutationsin
MYBPC3, R458H seemed to be associated with a clearly benign
course of disease, and that among those in MYH7, the patient
harboring D1652Y (patient ID 183) had an early onset of the
disease and a family history of sudden death, and the patient
with the L517M mutation (patient ID 248) evolved to the end-
stage phase of the disease.
Moreover,weobservedthatpatientsharboringamutationin
either MYH7 or MYBPC3 were tendentially younger than those
withoutamutationononeofthesegenes[respectively,33 16
yearsold(P¼0.10)and33 18yearsold(P¼0.08)vs.42 18
years old], suggesting that the disease might have an earlier
onset in these cases. More interestingly, patients harboring
a mutation in MYBPC3 were less prone to LV outﬂow tract
obstruction [2/19 (10.5%) vs. 36/106 (37%); P¼0.032]. Familial
presentation was more frequent in patients harboring a
mutation in MYH7 (78% vs. 38%; P¼0.031). On the contrary,
we did not observed any correlation between a mutation in
either MYH7 or MYBPC3 and other clinical variables, including
extension and severity of LV hypertrophy and history of
syncope or sudden death.
TABLE 4. Prediction of the Functional Effect of the Detected Genetic Variations
M With Polymorphism Phenotyping (PolyPhen)
Gene sequence variation Protein sequence variation Functional prediction PSIC score difference
Panel (a) MYH7
c.1331 A>G exon 12 N444S Probably damaging 2.484
c.4193 A>T exon 29 Q1398L Probably damaging 2.470
c.4954 G>T exon 33 D1652Y Possibly damaging 2.660
c.1549 C>A exon 13 L517M Possibly damaging 1.723
c.2795 T>A exon 21 M932K Benign 0.864
c.4472 C>G exon 30 S1491C Benign 0.155
Gene sequence variation Protein sequence variation Functional prediction PSIC score difference
Panel (b) MYBPC3
c.2002 C>T exon 19 R668C Probably damaging 2.572
c.3251 T>C exon 28 L1084P Probably damaging 2.346
c.1090 G>A exon 11 A364T Possibly damaging 1.760
c.2654 C>T exon 24 T885M Possibly damaging 1.983
c.2429 G>A exon23 R810Q Possibly damaging 1.947
c.472 G>A exon4 V158M (rs3729986) Benign 1.051
c.2311 G>A exon22 V771M Benign 1.435
c.1564 G>A exon15 A522T (rs11570082) Benign 0.206
c.1624 G>C exon 15 E542Q Benign 1.408
c.1813 G>C exon17 D605H Benign 0.055
c.1373 G>A exon14 R458H Benign 0.185
 Mutations and SNPs that cause an amino acid change; PSIC, position-speciﬁc independent counts—tells if the amino acid replacement may be incompatible with the spectrum of substitutions
observed at the position in the family of homologous proteins.
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Here we report an analysis of the entire coding and junction
regions of b-myosin heavy chain and cardiac myosin binding
protein—which are known to be the genes most frequently
implicated in HCM pathogenesis (Keren et al., 2008)—in a
cohort of 136 Italian patients (125 of which were unrelated)
presenting with HCM. We used DHPLC to identify variations,
which we then characterized qualitatively using bi-directional
sequencing. We found 3 novel mutations in MYH7 (2.4%) and 8
novelmutations inMYBPC3(6.4%) outof atotal of6 (4.8%)and
18 (14.4%) distinct mutations, respectively. Mutations in MYH7
were harbored by 7.2% of patients and in MYBPC3 by 15.2% of
patients.
The low number of mutations we found in these two genes
wasstrikingcomparedtopublishedreports(Kerenetal.,2008).
Although this ﬁnding might throw doubt on the sensibility or
suitability of the approached adopted, in our experience the
DHPLC conditions we use reach >95% sensibility in detecting
genetic variations. Moreover, a similar frequency of mutations
was reported in unrelated Spanish patients diagnosed with
HCM (Van Driest et al., 2005; Garcia-Castro et al., 2009). A
study conducted on a large French population reported higher
percentages(Richardetal.,2003),butthisdiscrepancycouldbe
duetogeneticheterogeneityortodifferencesintheratioofthe
sporadic to familiar cases in the two studies. Thus, the
frequency of sarcomeric mutations might be higher among
patients with a family history of the disease. Our ﬁndings might
also be due to a studied group of subjects that happened to be
extremely selective and made up of subphenotypes of mostly
(92%) asymptomatic or mildly symptomatic patients. In
addition, it was interesting to notice that a majority of the
mutationsfoundwerenovel:thiswasanotheraspectthatmade
us suppose that the group of patients studied was more
selective compared to other studied HCM populations.
Because none of the genetic variations we found were
present in our control group of 384 chromosomes, we
concluded that they can be regarded as disease-causing
mutations. We classiﬁed the missense mutations in terms of
severity, taking into consideration the amino acid position, the
frequency, and the chemical property differences of the amino
acid changes, using PolyPhen software (Table 4). However, it
should be considered that not all mutations that cause amino
acid changes have a deleterious effect, and that not all silent
mutationarebenign.Infact,anappreciableaffectontheprotein
can be registered if chemical properties of the new and original
amino acids are signiﬁcantly different (de la Chaux et al., 2007;
Gorlov et al., 2008) or if the location where the substitution
occurs is important (i.e., a site recognized for splicing or
completelyconservedresiduesintheproteinfamily).Anamino
acid change might be tolerated when it occurs in a position
not important for protein function or structure. Variations
in moderately conserved sites, instead, are more likely to
generate a diseased phenotype altering the clinical
manifestation, whereas a variation occurring in a more
polymorphic region might impact less negatively on the
protein’s function. However, in the latter case even if an overt
disease phenotype is not generated, the variation might be
clinically important if it modulates the severity of an overlying
disease or the response of a patient to a given therapy.
Besides substitutions in coding regions, we considered
also those that resided in the junction boundaries: these are
potentially important if they are responsible for alternative
splicing events generating a deﬁcient protein or a shortened
3’UTR. However, at the moment we cannot exclude the
possibility that the mutations found are not solely responsible
for disease. Only an extensive screening of other genes related
tocardiacfunctioncandeﬁnethisaspect.Infact,wedidnotﬁnd
a mutation in MYH7 or in MYBPC3 in 77.6% patients, suggesting
thatothergenes—sarcomeric-relatedorotherwise—mustbe
altered. Moreover, we need to pay attention to the number of
genetic variations (SNPs) that might play, in concert with
mutations, a pivotal role in the development of the disease.
Polymorphisms have a high frequency in the genome: more
than 2 million are thought to reside in the human genome,
approximately 100,000 of which might affect protein structure
or expression (Marian, 2001). We detected multiple
synonymous SNPs in a majority of patients, and found non-
synonymous SNPs in four patients. Although SNPs very likely
complicate the genetic scenario also of HCM, we can only
speculate at the moment which might have an effect on the
disease, such as in deﬁning drug response or clinical
manifestations (Brookes et al., 2000). For example, we found
two unrelatedpatientscarrying thesameMYBPC3 K754EfsX78
mutation:atthetimeofdiagnosis,bothwereasymptomatic,but
later on one required an implantable deﬁbrillator while the
other did not, suggesting that other genetic variations were
pivotal in the natural history of the disease in these patients.
Although we are aware that the patients might harbor
mutations in other genes related to HCM, the presence in one
of the patients of a delC in an intron of MYBPC3 may be
responsible for the different clinical proﬁles.
Finally, we did not identify any signiﬁcant differences in the
phenotypes manifested by the various mutations of the two
genesstudied.Thisisinagreementwithliteratureonunrelated
patients (Richard et al., 2003). We are tempted to speculate,
therefore, that HCM is probably more similar to a complex
disease than to a single-gene disease. Thus, it would be difﬁcult
to use partial genetic information to stratify-risk unrelated
patients.NovelgeneticandenvironmentalcausesofHCMmust
be uncovered in order to fully determine the pathogenic
mechanisms taking place in patients with HCM.
The ﬁndings obtained here have convinced us of the
necessityofadoptingabroadermethodology,forexample,454
Roche sequencing (Ronaghi et al., 1998; Margulies et al., 2005;
Bordoni et al., 2008) or ‘‘whole-exome sequencing’’ (Ng et al.,
2010), to carry out a more extensive investigation on a larger
groupofgenesandpatients.Sequencingdatawillbeﬁlteredand
the selected variations will be validated with a custom chip
(GoldenGate,Illumina,SanDiego,CA)(Lynchetal.,2009).We
expecttoidentifyfurthercausativemutationsandalistofSNPs
that may be involved in determining clinical events in the
development of HCM.
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